Estudio: Two-day versus seven-day course of levofloxacin in acute COPD exacerbation: a randomized controlled trial . Ther Adv Respir Dis 2022, Vol. 16: 1–10 Conclusion: Levofloxacin once daily for 2 days is not inferior to 7 days with respect to cure rate, need for additional antibiotics and hospital readmission in AECOPD. Our findings would improve patient compliance and reduce the incidence of bacterial resistance and adverse effects.
Presenta la Dra. Macarena Lagos
Diagnostic Performance of Electronic Nose Technology in Sarcoidosis. CHEST 2022; 161(3):738-747 INTERPRETATION: Patients with sarcoidosis can be distinguished from ILD and healthy control subjects by using eNose technology, indicating that this method may facilitate accurate diagnosis in the future. Further research is warranted to understand the value of eNose in monitoring sarcoidosis activity.
presentará el Dr. Juan Pablo Cuevas
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N Engl J Med 2023;388:1465-77 CONCLUSIONS RSVpreF vaccine prevented RSV-associated lower respiratory tract illness and RSV associated acute respiratory illness in adults (>60 years of age), without evident safety concerns.
Presentará el Dr. Felipe Cayupi
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med Vol 203, Iss 4, pp 484–492, Feb 15, 2021 Conclusions: A majority of patients with PAH still insufficiently improved after 6 months of initial combinations of oral drugs is identifiable at initial evaluation by hemodynamic response criteria added to risk scores.
Presentará el Dr. Marco Ayala
The Effect of Inhaled Corticosteroids on Pneumonia Risk in Patients With COPD-Bronchiectasis Overlap. A UK Population-Based Case-Control Study. CHEST 2023; 164(4):875-884 INTERPRETATION: ICS use does not augment further the already increased risk of hospitalisation for pneumonia associated with concomitant bronchiectasis in patients with COPD.
Presentará la Dra. Macarena Lagos